Cargando…
Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C
BACKGROUND AND AIMS: Chronic hepatitis C [CHC] is a risk factor for porphyria cutanea tarda [PCT]. To assess whether ledipasvir/sofosbuvir is effective for treating both PCT and CHC, we treated patients with CHC + PCT solely with ledipasvir/sofosbuvir and followed them for at least 1 year to assess...
Autores principales: | Bonkovsky, Herbert L., Rudnick, Sean P., Ma, Christopher D., Overbey, Jessica R., Wang, Kelly, Faust, Denise, Hallberg, Csilla, Hedstrom, Karli, Naik, Hetanshi, Moghe, Akshata, Anderson, Karl E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945827/ https://www.ncbi.nlm.nih.gov/pubmed/36811718 http://dx.doi.org/10.1007/s10620-023-07859-8 |
Ejemplares similares
-
Porphyria cutanea tarda and Sjogren's syndrome()
por: Fang, Su, et al.
Publicado: (2014) -
The D519G Polymorphism of Glyceronephosphate O-Acyltransferase Is a Risk Factor for Familial Porphyria Cutanea Tarda
por: Farrell, Colin P., et al.
Publicado: (2016) -
Porphyria cutanea tarda: a case report
por: Usta Atmaca, Hanife, et al.
Publicado: (2019) -
Scleral Compromise in Hereditary Porphyria Cutanea Tarda
por: Paez Soria, Eugenia Andrea, et al.
Publicado: (2021) -
Porphyria Cutanea Tarda in a Patient with Myelofibrosis
por: Serrano-Ordóñez, Ana, et al.
Publicado: (2023)